|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
AU2353384A
(en)
|
1983-01-19 |
1984-07-26 |
Genentech Inc. |
Amplification in eukaryotic host cells
|
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
|
AU6029594A
(en)
|
1993-01-15 |
1994-08-15 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
|
EP1621206A1
(en)
|
1994-12-12 |
2006-02-01 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric cytokines and uses thereof
|
|
AU6455896A
(en)
|
1995-07-11 |
1997-02-10 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
ATE319817T1
(de)
|
1996-04-24 |
2006-03-15 |
Univ Michigan |
Gegen inaktivierung resistenter faktor viii
|
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
ES2233036T3
(es)
|
1998-04-27 |
2005-06-01 |
Opperbas Holding B.V. |
Composicion farmaceutica que comprende factor viii y liposomas neutros.
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
CA2434097A1
(en)
|
2001-01-12 |
2002-08-08 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
|
|
EP2110385A1
(en)
|
2001-06-14 |
2009-10-21 |
The Scripps Research Institute |
Stabilized factor VIII with engineered disulfide bonds
|
|
US20080108560A1
(en)
|
2002-03-05 |
2008-05-08 |
Eli Lilly And Company |
Heterologous G-Csf Fusion Proteins
|
|
ES2343681T3
(es)
|
2002-04-29 |
2010-08-06 |
Stichting Sanquin Bloedvoorziening |
Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad.
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
DK1596887T3
(da)
|
2003-02-26 |
2022-06-20 |
Nektar Therapeutics |
Polymer-Faktor VIII-konjugat
|
|
AU2004239244C1
(en)
|
2003-05-06 |
2015-04-23 |
Bioverativ Therapeutics Inc. |
Clotting factor-Fc chimeric proteins to treat hemophilia
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
MXPA05013565A
(es)
|
2003-06-12 |
2006-03-09 |
Lilly Co Eli |
Proteinas de fusion analogas al glp-1.
|
|
BRPI0417916A
(pt)
|
2003-12-31 |
2007-04-10 |
Merck Patent Gmbh |
proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
NZ555032A
(en)
|
2004-11-12 |
2010-02-26 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
DK1835938T3
(da)
|
2004-12-27 |
2013-11-04 |
Baxter Int |
Polymer-von Willebrand-faktor-konjugater
|
|
WO2006108590A1
(en)
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
KR20080108147A
(ko)
|
2006-03-31 |
2008-12-11 |
백스터 인터내셔널 인코포레이티드 |
페질화된 인자 ｖｉｉｉ
|
|
KR101641899B1
(ko)
|
2006-06-14 |
2016-08-01 |
체에스엘 베링 게엠베하 |
혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질
|
|
KR101542752B1
(ko)
|
2006-12-22 |
2015-08-10 |
체에스엘 베링 게엠베하 |
연장된 생체내 반감기를 갖는 변형된 응고 인자
|
|
CN103739712B
(zh)
|
2008-06-24 |
2016-10-05 |
德国杰特贝林生物制品有限公司 |
具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
|
|
KR101808751B1
(ko)
*
|
2009-11-13 |
2017-12-13 |
그리폴스 테라퓨틱스 인코포레이티드 |
폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
|
|
AU2012340501A1
(en)
|
2011-12-19 |
2013-07-11 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
EP2804623B1
(en)
|
2012-01-12 |
2019-08-07 |
Bioverativ Therapeutics Inc. |
Chimeric factor viii polypeptides and uses thereof
|
|
US9458223B2
(en)
|
2012-02-15 |
2016-10-04 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor VIII binding affinity
|
|
CN104411716B
(zh)
|
2012-04-24 |
2018-09-07 |
诺和诺德股份有限公司 |
适用于治疗血友病的化合物
|
|
SG10201701037WA
(en)
|
2012-07-11 |
2017-03-30 |
Amunix Operating Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
|
DK2796145T3
(da)
*
|
2013-04-22 |
2018-01-29 |
Csl Ltd |
Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
|
|
CN105452289A
(zh)
|
2013-06-12 |
2016-03-30 |
诺和诺德股份有限公司 |
适用于治疗血友病的化合物
|
|
HK1223302A1
(zh)
*
|
2013-06-28 |
2017-07-28 |
Bioverativ Therapeutics Inc. |
具有xten的凝血酶可裂解连接子和其用途
|
|
JP6676551B2
(ja)
|
2014-07-02 |
2020-04-08 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
改変フォンウィルブランド因子
|
|
EP3297656B1
(en)
*
|
2015-05-22 |
2020-01-08 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
CA2986625A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Methods for preparing modified von willebrand factor
|
|
AU2017204955B2
(en)
*
|
2016-01-07 |
2021-04-01 |
CSL Behring Lengnau AG |
Mutated truncated von Willebrand Factor
|
|
AU2017205776B2
(en)
*
|
2016-01-07 |
2020-09-10 |
CSL Behring Lengnau AG |
Mutated von Willebrand factor
|